A detailed history of Chicago Partners Investment Group LLC transactions in Scynexis Inc stock. As of the latest transaction made, Chicago Partners Investment Group LLC holds 28,126 shares of SCYX stock, worth $28,126. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,126
Previous 28,916 2.73%
Holding current value
$28,126
Previous $57,000 28.07%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$1.27 - $2.23 $1,003 - $1,761
-790 Reduced 2.73%
28,126 $41,000
Q2 2024

Jul 31, 2024

SELL
$1.4 - $2.77 $12,520 - $24,772
-8,943 Reduced 23.62%
28,916 $57,000
Q1 2024

Apr 25, 2024

SELL
$1.39 - $2.21 $20,117 - $31,985
-14,473 Reduced 27.66%
37,859 $55,000
Q4 2023

Feb 23, 2024

SELL
$1.56 - $2.24 $1,542 - $2,215
-989 Reduced 1.85%
52,332 $116,000
Q3 2023

Oct 26, 2023

BUY
$1.93 - $3.64 $24,109 - $45,470
12,492 Added 30.6%
53,321 $121,000
Q2 2023

Aug 07, 2023

SELL
$2.38 - $3.67 $36,347 - $56,048
-15,272 Reduced 27.22%
40,829 $120,000
Q1 2023

Apr 26, 2023

BUY
$1.15 - $3.0 $195 - $510
170 Added 0.3%
56,101 $168,000
Q4 2022

Feb 09, 2023

SELL
$1.46 - $2.94 $10,888 - $21,926
-7,458 Reduced 11.77%
55,931 $87,000
Q3 2022

Nov 09, 2022

BUY
$1.83 - $2.93 $17,681 - $28,309
9,662 Added 17.98%
63,389 $141,000
Q2 2022

Aug 04, 2022

BUY
$1.77 - $3.87 $6,256 - $13,680
3,535 Added 7.04%
53,727 $124,000
Q1 2022

May 20, 2022

BUY
$3.56 - $6.66 $30,320 - $56,723
8,517 Added 20.44%
50,192 $106,000
Q4 2021

Feb 15, 2022

BUY
$4.94 - $7.69 $205,874 - $320,480
41,675 New
41,675 $189,000

Others Institutions Holding SCYX

About SCYNEXIS INC


  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $32.7M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Chicago Partners Investment Group LLC Portfolio

Follow Chicago Partners Investment Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chicago Partners Investment Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chicago Partners Investment Group LLC with notifications on news.